Tagged Articles

Xarelto 169 articles

New evidence could lead to Xarelto re-trial


Attorneys for a woman who suffered a major bleeding event after taking the blood thinner Xarelto are seeking a new trial after discovering new evidence that questions the accuracy of statements made by the drug’s makers. Jurors found in favor of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer. During the trial, jurors were told by the drug companies that there was no effective test to determine whether patients were at an increased risk for internal bleeds while taking Xarelto, and dismissed plaintiff Dora Mingo’s expert witness’ testimony that a lab test called prothrombin time – or PT – would not ... Read More

Korea adds severe skin reaction warning to Xarelto


Korea’s Ministry of Food and Drug Safety (MFDS) is requiring an update to the safety label of the blood thinner Xarelto to include new warnings regarding the risk of the serious and sometimes fatal skin reactions known as Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The warning comes after the European Commission issued a public safety alert regarding serious skin conditions with Xarelto. Most side effects were reported within the first week of treatment. The ministry collected opinions and reviewed them last month and determined that the warnings should also come with a recommendation for doctors to discontinue ... Read More

Eliquis may be safer, more effective than Xarelto


Among the new oral anticoagulants on the market, Xarelto remains the top selling. But Eliquis is closing in on Xarelto. That gap may get even tighter after the Vascular Interventional Advances (VIVA) annual conference in Las Vegas, Nevada, during which medical professionals surmised that Eliquis appeared safer and more convenient that its rival Xarelto. Xarelto and Eliquis were the second and third non-vitamin K oral anticoagulants to be approved in the U.S., respectively. Pradaxa was the first and Savaysa was the last. Both Pradaxa and Savaysa require lead-in therapy with a subcutaneous anticoagulant, which causes pain, inconvenience, additional costs, and ... Read More

Xarelto users should avoid grapefruit


People who take the blood thinner Xarelto should limit their intake of grapefruit while taking the drug, cautions Joe Graedon and Teresa Graedon with the People’s Pharmacy published in myAJC. Xarelto hit the market in 2011 and was promoted as a novel oral anticoagulant that was just as effective but far more convenient than the long-used warfarin. For decades, warfarin had been the go-to treatment for the prevention of strokes in patients with the common heart rhythm abnormality called atrial fibrillation. But taking warfarin came at a price. The blood thinner can interact adversely with numerous medications or foods. For ... Read More

Xarelto cases in state court start soon


Drug maker Bayer asked the Philadelphia Court of Common Pleas to dismiss punitive damages from two of the first bellwether trials scheduled pending in state court involving Xarelto side effects. Meanwhile, attorneys representing people suing Xarelto’s makers filed two motions seeking to bar defense experts from testifying that attorney advertising affects the incidence of bleeding events, or that bleeding events can be beneficial if they lead to early diagnosis of other conditions. Bayer asked the court to apply either New Jersey law or German law to the cases, which would free the drug company from paying punitive damages. The motion ... Read More

Xarelto data: benefits don’t outweigh the harms


Johnson & Johnson’s Janssen Pharmaceuticals and Bayer have been fast to tout the news that their blood thinner Xarelto in combination with aspirin cut the risk of cardiovascular death, heart attacks or strokes in patients with coronary artery disease and/or peripheral artery disease (PAD/CAD) – a population that’s at higher risk for cardiovascular events. But, while it’s a win for the drug companies, it’s not so much for patients, according to Dr. John Mandrola’s commentary in Medscape. If approved for the prevention of strokes and heart attacks in PAD/CAD patients based on COMPASS data, the drug would become a candidate ... Read More

Major bleeding reported in Xarelto-aspirin combo study


Johnson & Johnson’s Janssen Pharmaceuticals and Bayer are touting new data that shows their blood thinner Xarelto when combined with aspirin significantly reduced the risk of heart attacks and strokes in patients with stable coronary or peripheral artery disease. However, the risk of major bleeding events was significantly higher in patients taking both meds at the same time. Data from the so-called COMPASS study, which was funded by Bayer, was presented at the ESC Congress in 2017 in August and published in The New England Journal of Medicine. It was the largest study involving Xarelto, with more than 27,000 patients enrolled. ... Read More

Xarelto contraindications ignored by some doctors


Abut 38,000 people in the U.K. suffer from the common heart rhythm abnormality atrial fibrillation but are taking blood thinners like Xarelto or Eliquis along with other medications that are contraindicated for use with anticoagulants, which can cause harm to these patients, according to a study published in the British Journal of General Practice. The study examined data from 645 general practices within the U.K.’s Health Improvement Network of primary care records. Researchers pulled data from patients diagnosed with atrial fibrillation as well as those prescribed a blood thinner but had a contraindication for those medications. Contraindications include a specific ... Read More

Xarelto sales could double with new indication


Sales of the blood thinner Xarelto could more than double overnight if its indication is expanded to include the prevention of heart attacks and strokes in patients with atherosclerosis, a buildup of fats, cholesterol, and other substances in and on the artery walls, analysts say. Xarelto, made by Johnson & Johnson’s Janssen Pharmaceuticals and Bayer, has been on the market since 2011. It is approved to prevent strokes in patients with atrial fibrillation, a condition that affects about 25 million people. Xarelto is also approved for the prevention and treatment of deep vein thrombosis and pulmonary embolism, and the prevention ... Read More

Fourth Xarelto trial could bring justice to victims


A different set of circumstances in the fourth bellwether trial involving bleeding risks with the blood thinner Xarelto could break the winning streak enjoyed by drug makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer. Patients in the three previous Xarelto lawsuits to go to trial had failed to persuade jurors that Janssen and Bayer did not adequately warn patients that the blood thinner could cause gastrointestinal bleeds, brain hemorrhages and bleeding deaths. It is unusual for bellwether trials in pharmaceutical litigation to repeatedly fall in favor of the defendants, but those suing the drug companies refuse to give up the ... Read More